On October 17, 2022 Nexi reported that it had attracted Series A investment worth 22 billion won (Press release, NEX-I, OCT 17, 2022, View Source;mode=VIEW&num=31&category=&findType=&findWord=&sort1=&sort2=&page=2 [SID1234643439]). In addition to existing investors such as DSC Investment, Schmidt, Atinum Investment, and Hana Ventures, six institutions including Stone Bridge Ventures, TS Investment, CJ Investment, Wonik Investment Partners, Medytox Venture Investment, and GC Green Cross participated as new investors in this investment. Nexi’s cumulative investment has increased to 27 billion won, including this round.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NexI plans to use this investment for research and development and preclinical testing of the company’s leading candidate substances, ‘NXI-101’ and ‘NXI-201’. Kyung-wan Yoon, CEO of Nexi, said, "Our goal is for NXI-101 to enter clinical trials in 2024."

Nexi, established in 2021, has a platform technology to discover factors that cause refractoriness to existing immunotherapy drugs. The company explains that it is a platform technology that discovers the cause of anti-cancer immunotherapy drugs not working well and then develops a drug that targets and eliminates or suppresses the cause.

GC Green Cross, which participated in this investment, plans to seek mid- to long-term cooperation with NexI as a strategic investor (SI).